Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity

MLA

Elizabeth M. Jaffee, et al. Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-Cell–Mediated Anticancer Activity. Apr. 2023. EBSCOhost, https://doi.org/10.1158/2326-6066.c.6549304.v1.

APA

Elizabeth M. Jaffee, Todd Armstrong, Valerie Z. Wall, Skylar Woolman, Kayla Cruz, Blake Scott, Brian Christmas, Tara M. Robinson, John-William Sidhom, Evanthia Roussos Torres, Bibhav Poudel, & Hayley S. Ma. (2023). Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity. https://doi.org/10.1158/2326-6066.c.6549304.v1

Chicago

Elizabeth M. Jaffee, Todd Armstrong, Valerie Z. Wall, Skylar Woolman, Kayla Cruz, Blake Scott, Brian Christmas, et al. 2023. “Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-Cell–Mediated Anticancer Activity,” April. doi:10.1158/2326-6066.c.6549304.v1.